CG Oncology, Inc. Common stock (CGON)

CG Oncology, Inc. Common stock (CGON) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $5.3B; returns 1 day -1.3%, 1 week +3.1%, 1 year +47.0%.

CG Oncology, Inc. (CGON) is a late-stage clinical biopharmaceutical company dedicated to developing cretostimogene grenadenorepvec, an intravesical oncolytic immunotherapy designed for non-muscle invasive bladder cancer (NMIBC).

Groups CGON belongs to

• Biotechnology
• Oncology
• Clinical Stage Biopharma
• Biopharmaceutical
• Clinical Stage
• Immunotherapy
• Healthcare
• Cancer Therapeutics
• Life Sciences

CGON financial model: income statement, cash flow and balance sheet